The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Peptide therapeutics: current status and future directions
Open accessAbstract
Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates. Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stability of Protein Pharmaceuticals: An Update
Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0045-6 · Cited by 1,098
Future directions for peptide therapeutics development
Kaspar, A. A., & Reichert, J. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.011 · Cited by 750
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Hamley, I. W. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700861 · Cited by 618
The uses and properties of PEG-linked proteins.
Delgado, C., Francis, G. E., & Fisher, D. (1992) · PubMed · Cited by 420
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
The Human Intestinal Microbiome: A New Frontier of Human Biology
Hattori, M., & Taylor, T. D. (2009) · DNA Research · doi:10.1093/dnares/dsn033 · Cited by 281
Neuroactive Peptides as Putative Mediators of Antiepileptic Ketogenic Diets
Giordano, C., Marchiò, M., Timofeeva, E., & Biagini, G. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00063 · Cited by 150
Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer
Okarvi, S. M. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.017 · Cited by 145
Unraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 133
Antimicrobial peptides and proteins in mycobacterial therapy: Current status and future prospects
Padhi, A., Sengupta, M., Sengupta, S., Roehm, K. H., & Sonawane, A. (2014) · Tuberculosis · doi:10.1016/j.tube.2014.03.011 · Cited by 128
Diversity of Conotoxin Gene Superfamilies in the Venomous Snail, Conus victoriae
Robinson, S. D., Safavi-Hemami, H., McIntosh, L., Purcell, A. W., Norton, R. S., & Papenfuss, A. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087648 · Cited by 126
Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512046 · Cited by 123
Liraglutide: the therapeutic promise from animal models
Knudsen, L. B. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02499.x · Cited by 102
Peptides in body fluids and tissues as markers of disease
Schulte, I., Tammen, H., Selle, H., & Schulz‐Knappe, P. (2005) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.5.2.145 · Cited by 102
Fosgerau, K., Jessen, L., Tolborg, J. L., Østerlund, T., Larsen, K. S., Rolsted, K., Brorson, M., Jelsing, J., & Neerup, T. S. R. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01676.x · Cited by 93
Self-citationHenry, R. R., Rosenstock, J., Logan, D. K., Alessi, T. R., Luskey, K. L., & Baron, M. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.12.009 · Cited by 82
Functional selectivity of GPCR signaling in animals
Zhou, L., & Bohn, L. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.11.010 · Cited by 76
Proof of concept for next-generation nanoparticle drugs in humans
Sheridan, C. (2012) · Nature Biotechnology · doi:10.1038/nbt0612-471 · Cited by 69
Buchwald, H., Dorman, R. B., Rasmus, N. F., Michalek, V. N., Landvik, N. M., & Ikramuddin, S. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.01.032 · Cited by 59
Bao, W., Holt, L. J., Prince, R., Jones, G. X., Aravindhan, K., Szapacs, M., Barbour, A., Jolivette, L. J., Lepore, J. J., Willette, R. N., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-148 · Cited by 55
Actobiotics™ as a Novel Method for Cytokine Delivery: The Interleukin‐10 Case
Steidler, L., Rottiers, P., & Coulie, B. J. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05067.x · Cited by 51
Directional Assembly of α-Helical Peptides Induced by Cyclization
Sim, S., Kim, Y., Kim, T., Lim, S., & Lee, M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3098756 · Cited by 34
Functional Reconstruction of Structurally Complex Epitopes using CLIPSTM Technology#
Timmerman, P., Puijk, W. C., Boshuizen, R. S., van Dijken, P., Slootstra, J. W., Beurskens, F. J. M., Parren, P. W. H. I., Huber, A., Bachmann, M. F., & Meloen, R. H. (2009) · The Open Vaccine Journal · doi:10.2174/1875035400902010056 · Cited by 25
Research works printed but not linked: 4
- Riber, 2013, A novel glucagon analogue, ZP-GA-1, displays increased chemical and physical stability in liquid formulation, Diabetes, 62, A99
- Houston, 1996, Lactam bridge stabilization of alpha-helices: the role of hydrophobicity in controlling dimeric versus monomeric alpha-helices, Biochemistry, 35, 10041, 10.1021/bi952757m · doi:10.1021/bi952757m
- Fosgerau, 2011, The new glucagon-GLP-1 dual agonist ZP2929 in combination with long-acting insulin improves glycemic control without causing weight loss in db/db mice, Diabetes, 60, A408
- Just, 2014, The novel GLP-1-GLP-2 dual agonist ZP-GG-72 increases intestinal growth and improves insulin sensitivity in DIO mice, Diabetes, 63, A1
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex
Lamiable, A., Thévenet, P., Rey, J., Vavrusa, M., Derreumaux, P., & Tufféry, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw329 · Cited by 1,053
Metadata
- Authors
- Fosgerau, K., & Hoffmann, T.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 20
- Issue
- 1
- Pages
- 122-128
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W1992450378
- Cited by
- 3,030
- References
- 24
- FWCI
- 55.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/3.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.